Segment Information (Details) $ in Thousands	3 Months Ended
Mar. 31, 2026 USD ($) segment	Mar. 31, 2025 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment	1
Segment Reporting Information [Line Items]
Total research and development expenses	$ 65,591	$ 60,729
Total selling, general, and administrative expenses	65,070	63,422
Reportable Segment
Segment Reporting Information [Line Items]
Personnel compensation and related costs	18,470	24,079
Licensing fees	22,000	19,997
CROs/CMOs/Investigators expenses	19,540	9,830
Other costs	5,581	6,823
Total research and development expenses	65,591	60,729
Clinical programs	31,090	28,092
Pre-Clinical programs	11,716	3,314
Unallocated research and development expenses	22,785	29,323
Personnel compensation and related costs	41,060	40,643
Other costs	24,010	22,779
Total selling, general, and administrative expenses	65,070	63,422
Selling and marketing expenses	43,438	41,939
General and administrative expenses	$ 21,632	$ 21,483

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1